Another biotech shuffles its C-suite as Silence CEO steps down
Silence Therapeutics became the latest biotech to see its chief executive hit the exit.
Mark Rothera is leaving effective immediately, Silence announced late Monday, marking the end of his roughly 17-month tenure. In his place, the biotech elevated CFO Craig Tooman to the CEO and president roles, where he’ll attempt to shepherd a slate of early-stage and preclinical RNAi programs forward.
Rhonda Hellums, previously Silence’s VP of finance, has been appointed to Tooman’s old CFO role.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.